Ernexa Therapeutics
ERNA | NASDAQ
$1.69
+$0.01 (+0.60%)
At close: Nov 16, 2026, 4:00 PM ET
$1.68
-$0.01 (-0.59%)
After-hours:
Nov 16, 2026, 5:58 PM ET
Ernexa Therapeutics Company Profile
Company profile explainedCompany Profile
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Key Executives
| Name | Position |
|---|---|
| Sanjeev Luther | Chief Executive Officer, President & Director |
| Mark J. Keeley CITP | Chief Financial Officer |
| Deborah Vee Wild | Head of CMC & Operations |
| Dorothy J. Clarke | General Counsel |
| Kanika Chawla | Senior Vice President of Technical Operations (Consultant) |
| Robert Hamilton Pierce | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 15, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 3 | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
Ernexa Therapeutics
| Country | United States |
| IPO Date | Aug 29, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Sanjeev Luther |
Contact Details
10355 Science Center Drive Cambridge,
Massachusetts 02141 United States
Stock Details
| Ticker Symbol | ERNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000748592 |
| CUSIP Number | 114082407 |
| ISIN Number | US1140824079 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ERNA